Annual and sustainability report 2025
Bringing brilliant ideas to life.
Swedish Orphan Biovitrum AB (publ) (Sobi®) is a global biopharma company. Throughout its history, Sobi has built a strong legacy rooted in collaboration and scientific expertise. This foundation continues to guide the company as it unlocks the potential of breakthrough innovations and transforms everyday life for people living with rare diseases.
A year of strong execution and strategic progress
"We have delivered significant results in the business in 2025 and importantly made tremendous progress with our pipeline setting Sobi up for significant longer term growth potential. We look forward with excitement to bringing these medicines to more and more people in need of innovative treatments."
Guido Oelkers, President & CEO
Key figures 2025
28,238
total revenue, SEK M
11,341
adjusted EBITA, SEK M
40%
adjusted EBITA, margin
Haematology
19,116
revenue, SEK M
16%
growth
Immunology
7,809
revenue, SEK M
-6%
growth
Specialty Care
1,312
revenue, SEK M
4%
growth
Sustainability
Sobi aims to improve the lives of people with rare and severe diseases, and this is also the company’s main contribution to sustainable development. A systematic engagement in sustainability creates value for both patients and other stakeholders, as well as for society. The sustainability strategy, based on a comprehensive analysis of impacts, risks and opportunities in the Sobi operations and value chain and shaped to meet requirements of the CSRD, groups Sobi’s 21 material matters into two main themes.
Maintain commitment to patients
- Access to treatment
- Patient centricity and engagement
- Patient and product safety
- Responsible marketing and sales
- Ethical R&D
Always act responsibly
- Safe, healthy and fair working conditions
- A fair and inclusive workplace
- Reduction of environmental and climate impact
- Reduced resource consumption
- Responsible sourcing
- Compliance and corruption prevention
>53,000
patients treated with a Sobi medicine during 2025
1,000 M
IUs of factor donated to WFH’s Humanitarian Aid Program since start
79 (+4)
points out of 100 in Sobi’s annual Engagement survey
22%
reduction of emissions in scope 1 and 2 between 2024 and 2025
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Here we present our most recent press releases, stories, news articles, and images.
Find out more about our business and financial performance.
Every day, we work actively to find better ways to understand and meet patient needs.
- About
- Therapeutic areas
- Medicines
- Sustainability
- News & Stories
- Investors
- Careers